随着时间的推移，抗生素可以再次获得更强的盈利能力，因为相关公司可以销售更多其他药物，因此逐渐降低对昂贵激励政策的需求。
Over time, antibiotics could become more profitable again, as engaged companies sell more of their other drugs and the need for costly incentives diminishes.